AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

While it was welcomed by advocates as a way of helping farmers make their plants hardier and yields higher, it was also met with concern from some who say it could threaten trade opportunities and cau ...

It’s not often that a news story unsettles me in the way one I spotted in this very newspaper last week has done. Apparently, ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

Profluent Bio announced a research collaboration with the Rett Syndrome Research Trust (RSRT) to design novel base editors to ...

The up to $1.4M collaboration will enable manufacturing “universal” islets containing a drug-inducible safety feature designed to make curative therapies accessible without the need for chronic ...

Diacylglycerol O-acyltransferase 1 (DGAT1), the rate-limiting enzyme in triacylglycerol (TAG) biosynthesis, is a crucial ...

With the global technical textiles market heading toward $200B by 2030 , KBLB’s timing could enable early adoption and prototype work for 2026 procurement cycles, especially in high-performance and ...

The food biotechnology market is projected to grow substantially over the next decade, rising from an estimated USD 32.5 ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

Urban Legends That Turned Out to be True: <a href=" ►25 Facts About Things You've Always Heard But Aren't True: <a href=" No ...

Sam Altman's support for a gene-editing project aiming to create disease-free babies raises urgent ethical, scientific, and ...